An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons

Brain Research

Volumn 1395, Issue , 2011, Pages 94-107

  Khodr, Christina E ^a   Sapru, Mohan K ^a   Pedapati, Jyothi ^a   Han, Ye ^a   West, Neva C ^a   Kells, Adrian P ^b   Bankiewicz, Krystof S ^b   Bohn, Martha C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Neurodegeneration; RNAi; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; AMPHETAMINE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; SHORT HAIRPIN RNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FORELIMB; GENE SILENCING; GENE THERAPY; MALE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RNA SEQUENCE; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; FORELIMB; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MALE; NEURONS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

RATTUS;

EID: 79957923807     PISSN: 00068993     EISSN: 00068993     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.04.036     Document Type: Article

References (51)

1. Alerte, T.N., Akinfolarin, A.A., Friedrich, E.E., Mader, S.A., Hong, C.S., Perez, R.G., 2008. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett. 435, 24-29.
2. Bellani, S., Sousa, V.L., Ronzitti, G., Valtorta, F., Meldolesi, J., Chieregatti, E., 2010. The regulation of synaptic function by alpha-synuclein. Commun. Integr. Biol. 3, 106-109.
3. Bjorklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., Mandel, R.J., 2000. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886, 82-98.
4. Blomer, U., Naldini, L., Kafri, T., Trono, D., Verma, I.M., Gage, F.H., 1997. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641-6649. (Pubitemid 27355322)
5. Boudreau, R.L., Monteys, A.M., Davidson, B.L., 2008. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14, 1834-1844.
6. Boudreau, R.L., Martins, I., Davidson, B.L., 2009. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 17, 169-175.
7. Boudreau, R.L., Davidson, B.L., 2010. RNAi therapeutics for CNS disorders. Brain Res. 1338, 112-121.
8. Cannon, J.R., Greenamyre, J.T., 2010. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog. Brain Res. 184, 17-33.
9. Castanotto, D., Sakurai, K., Lingeman, R., Li, H., Shively, L., Aagaard, L., Soifer, H., Gatignol, A., Riggs, A., Rossi, J.J., 2007. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 35, 5154-5164. (Pubitemid 47394199)
10. Chesselet, M.F., 2008. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp. Neurol. 209, 22-27.
11. Choi-Lundberg, D.L., Lin, Q., Chang, Y.N., Chiang, Y.L., Hay, C.M., Mohajeri, H., Davidson, B.L., Bohn, M.C., 1997. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841. (Pubitemid 27074886)
12. Connor, B., Kozlowski, D.A., Schallert, T., Tillerson, J.L., Davidson, B.L., Bohn, M.C., 1999. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6, 1936-1951. (Pubitemid 30076864)
13. Couto, L.B., High, K.A., 2010. Viral vector-mediated RNA interference. Curr. Opin. Pharmacol. 10, 534-542.
14. Diederichs, S., Jung, S., Rothenberg, S.M., Smolen, G.A., Mlody, B.G., Haber, D.A., 2008. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc. Natl. Acad. Sci. U. S. A. 105, 9284-9289.
15. Doxakis, E., 2010. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 285, 12726-12734.
16. Ehlert, E.M., Eggers, R., Niclou, S.P., Verhaagen, J., 2010. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci. 11, 20.
17. Feany, M.B., Bender, W.W., 2000. A Drosophila model of Parkinson's disease. Nature 404, 394-398. (Pubitemid 30164341)
18. Fernagut, P.O., Chesselet, M.F., 2004. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17, 123-130.
19. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811. (Pubitemid 28099681)
20. Fleming, S.M., Salcedo, J., Fernagut, P.O., Rockenstein, E., Masliah, E., Levine, M.S., Chesselet, M.F., 2004. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24, 9434-9440. (Pubitemid 39426179)
21. Gorbatyuk, O.S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A.S., Sullivan, L.F., Mandel, R.J., Chen, W., Meyers, C., Manfredsson, F.P., Muzyczka, N., 2010. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 18, 1450-1457.
22. Graybiel, A.M., Moratalla, R., Robertson, H.A., 1990. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. U. S. A. 87, 6912-6916.
23. Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., Marion, P., Salazar, F., Kay, M.A., 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541. (Pubitemid 44050158)
24. Han, Y., Chang, Q.A., Virag, T., West, N.C., George, D., Castro, M.G., Bohn, M.C., 2010. Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors. Gene Ther. 17, 616-625.
25. Han, Y., Khodr, C.E., Sapru, M., Pedapati, J., Bohn, M.C., 2011. A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res. 1386, 15-24.
26. Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y., Mochizuki, H., 2006. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells fromcell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 341, 1088-1095.
27. Junn, E., Lee, K.W., Jeong, B.S., Chan, T.W., Im, J.Y., Mouradian, M. M., 2009. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U. S. A. 106, 13052-13057.
28. Kearns, C.M., Gash, D.M., 1995. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672, 104-111.
29. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T.E., Muzyczka, N., Mandel, R.J., Bjorklund, A., 2002. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791. (Pubitemid 37465827)
30. Kirik, D., Annett, L.E., Burger, C., Muzyczka, N., Mandel, R.J., Bjorklund, A., 2003. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a newprimatemodel of Parkinson'sdisease. Proc.Natl.Acad. Sci.U. S. A. 100, 2884-2889.
31. Lee, V.M., Trojanowski, J.Q., 2006. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33-38. (Pubitemid 44479831)
32. Lewis, J., Melrose, H., Bumcrot, D., Hope, A., Zehr, C., Lincoln, S., Braithwaite, A., He, Z., Ogholikhan, S., Hinkle, K., Kent, C., Toudjarska, I., Charisse, K., Braich, R., Pandey, R.K., Heckman, M., Maraganore, D.M., Crook, J., Farrer, M.J., 2008. In vivo silencing of alpha-synuclein using naked siRNA. Mol. Neurodegener. 3, 19.
33. Lo Bianco, C., Ridet, J.L., Schneider, B.L., Deglon, N., Aebischer, P., 2002. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 99, 10813-10818.
34. Lo Bianco, C., Deglon, N., Pralong, W., Aebischer, P., 2004. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 17, 283-289.
35. Mandel, R.J., Spratt, S.K., Snyder, R.O., Leff, S.E., 1997. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. U. S. A. 94, 14083-14088.
36. Maraganore, D.M., de Andrade, M., Elbaz, A., Farrer, M.J., Ioannidis, J.P., Kruger, R., Rocca, W.A., Schneider, N.K., Lesnick, T.G., Lincoln, S.J., Hulihan, M.M., Aasly, J.O., Ashizawa, T., Chartier-Harlin, M.C., Checkoway, H., Ferrarese, C., Hadjigeorgiou, G., Hattori, N., Kawakami, H., Lambert, J.C., Lynch, T., Mellick, G.D., Papapetropoulos, S., Parsian, A., Quattrone, A., Riess, O., Tan, E.K., Van Broeckhoven, C., 2006. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661-670. (Pubitemid 44200637)
37. McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A. M., Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B., Carter, B.J., Davidson, B.L., 2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 105, 5868-5873.
38. McCormack, A.L., Mak, S.K., Henderson, J.M., Bumcrot, D., Farrer, M.J., Di Monte, D.A., 2010. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One. 5, e12122.
39. Rodriguez-Lebron, E., Gouvion, C.M., Moore, S.A., Davidson, B.L., Paulson, H.L., 2009. Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol. Ther. 17, 1563-1573.
40. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., Bohn, M.C., 2006. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198, 382-390.
41. Sauer, H., Rosenblad, C., Bjorklund, A., 1995. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U. S. A. 92, 8935-8939.
42. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L., Bland, S.T., 2000. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777-787. (Pubitemid 30103682)
43. Scherr, M., Eder, M., 2007. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 6, 444-449. (Pubitemid 46393448)
44. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., 1997. Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
45. Tomac, A., Lindqvist, E., Lin, L.F., Ogren, S.O., Young, D., Hoffer, B.J., Olson, L., 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335-339.
46. Towne, C., Setola, V., Schneider, B.L., Aebischer, P., 2011. Neuroprotection by gene therapy targeting mutant SOD1 in Individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol. Ther. 19, 274-283.
47. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W., Yankner, B.A., 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606.
48. Yi, R., Doehle, B.P., Qin, Y., Macara, I.G., Cullen, B.R., 2005. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs andmicroRNAs. RNA 11, 220-226. (Pubitemid 40165636)
49. Yuan, B., Sierks, M.R., 2009. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci. Lett. 459, 16-18.
50. Zufferey, R., Dull, T., Mandel, R.J., Bukovsky, A., Quiroz, D., Naldini, L., Trono, D., 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880. (Pubitemid 28520853)
51. Zufferey, R., Trono, D., 2002. Production of High-Titer Lentiviral Vectors. Current Protocols in Human Genetics. Vol. John Wiley & Sons, Inc., New York.